A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

A phase II clinical study of 13‐deoxy, 5‐iminodoxorubicin (GPX‐150) with metastatic and unresectable soft tissue sarcoma

Abstract Background 13‐Deoxy, 5‐iminodoxorubicin (GPX‐150) is a doxorubicin (DOX) analog synthesized to reduce the formation of reactive oxygen species and the cardiotoxic metabolite, doxorubiciniol, the two pathways that are linked to the irreversible, cumulative dose‐dependent cardiotoxicity of DO...

Full description

Bibliographic Details
Main Authors: Brian A. Van Tine, Mark Agulnik, Richard D. Olson, Gerald M. Walsh, Arthur Klausner, Nicole E. Frank, Todd T. Talley, Mohammed M. Milhem
Format: Article
Language:English
Published: Wiley 2019-06-01
Series:Cancer Medicine
Subjects:
anthracyclines
cardiotoxicity
doxorubicin
GPX‐150
phase II
soft tissue sarcoma
Online Access:https://doi.org/10.1002/cam4.2136

Similar Items

Similar Items